ECRIN received a positive funding decision from the European Commission’s Horizon 2020 programme for the creation of a Paediatric Clinical Research Infrastructure Network (PedCRIN).
ECRIN’s Portuguese national scientific partner has authored a new publication entitled “Investigator-initiated clinical trials conducted by the Portuguese Clinical Research Infrastructure Network (PtCRIN).”
ReveraGen BioPharma Inc Initiates VISION-DMD Phase 2a Study for Treatment of Duchenne Muscular Dystrophy
Enrolment has begun in the phase 2a clinical trial of the orphan drug vamorolone (VBP15) in the treatment of ambulatory boys with Duchenne muscular dystrophy (DMD).
ECRIN’s Independent Certification Board certified two clinical trial units (CTUs) as high-quality data centres in July 2016.
ECRIN signed a memorandum of understanding (MoU) in July 2016 with the Foundation for Biomedical Research and Innovation (FBRI) in Japan and the Oswaldo Cruz Foundation (Fundacao Oswaldo Cruz, FIOCRUZ) in Brazil.
ECRIN's Director General, Jacques Demotes, provides a brief report on this year's celebration of International Clinical Trials Day (ICTD).
The FAIR-PARK II trial (Conservative Iron Chelation as a Disease-Modifying Strategy in Parkinson's Disease, PD) has held site initiation visits at all participating sites in France (sponsor country). The first patient was enrolled in February 2016.
New Publication: Evidence-based clinical practice: Overview of threats to the validity of evidence and how to minimise them
ECRIN has contributed to a new scientific publication entitled "Evidence-based clinical practice: Overview of threats to the validity of evidence and how to minimise them".
The application system is now open for the C-COMEND course, a two-year European training project supported by the Erasmus plus programme, which started on 1 November 2015.
As part of the CORBEL project, ECRIN has prepared a short survey for users of research infrastructures (RIs) in Europe.
The European Molecular Biology Laboratory (EMBL) is holding a conference on Core Technologies for Life Science (CTLS) in Heidelberg, Germany from June 12th to 15th, 2016.
The meeting aims to increase awareness of ECRIN and its Czech national scientific partner – the Czech Clinical Research Infrastructure Network (CZECRIN) – and to address issues related to personalised medicine and multinational clinical trials.
ECRIN has been listed as an “ESFRI Landmark” on the European Strategy Forum on Research Infrastructures (ESFRI) Roadmap 2016, launched on March 10th, 2016 in Amsterdam.